Data from Pharmawand - Curated by EPG Health - Date added 11 July 2018

Insmed Incorporated announced that the Division of Antimicrobial Products of the FDA has notified the company of a planned advisory committee meeting to review data supporting Insmed’s New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) (Arikayce) for adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). The tentative date for the meeting is set for August 7, 2018.

“Currently there are no approved therapies for this rare, progressive and potentially fatal disease, representing a significant unmet need,” commented Will Lewis, President and Chief Executive Officer of Insmed.

The Company has previously announced that the FDA accepted and considered the NDA for ALIS filed on May 27, 2018. The FDA granted Insmed's request for Priority Review and has set an action date of 28 September 2018 under the Prescription Drug User Fee Act (PDUFA). Priority Review applies to an application for a drug that treats a serious condition and that, if approved, would provide a significant improvement in safety or effectiveness. The FDA has previously designated ALIS as an orphan drug, a breakthrough therapy and a Qualified Infectious Disease Product (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Related Content